Trials / Completed
CompletedNCT02167035
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
Pilot Study Comparison of Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Cornerstone Health Care, PA · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combigan Two Times Daily (BID) | |
| DRUG | Simbrinza Three Times Daily (TID) |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2014-06-18
- Last updated
- 2018-10-24
- Results posted
- 2018-10-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02167035. Inclusion in this directory is not an endorsement.